Back to Newsroom

Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014

LOS ANGELES, Calif., Sept. 3, 2014 – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that data from a Phase II clinical trial of its investigational drug PB272 (neratinib) for the treatment of patients with non-small cell lung cancer (NSCLC) that has a HER2 mutation will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) 2014 Congress, September 26-30, in Madrid, Spain.  The presentation entitled “Neratinib with or without temsirolimus in patients with non-small cell lung cancer carrying HER2 somatic mutations:  An international randomized Phase II study” will occur on September 29, 2014.

Click here to read more